{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:07:42Z","timestamp":1784038062330,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]},{"name":"State Key Laboratory of Neurology and Oncology Drug Development"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-026-02153-9","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:36Z","timestamp":1777374876000},"page":"1703-1713","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System"],"prefix":"10.1007","volume":"48","author":[{"given":"Hai-yu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-yu","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-jin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-gang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"2153_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26216677","author":"MAS Abourehab","year":"2021","unstructured":"Abourehab MAS, Alqahtani AM, Youssif BGM, et al. Globally approved EGFR inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26216677.","journal-title":"Molecules"},{"issue":"Suppl 4","key":"2153_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/s0959-8049(01)00230-1","volume":"37","author":"Y Yarden","year":"2001","unstructured":"Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(Suppl 4):S3-8. https:\/\/doi.org\/10.1016\/s0959-8049(01)00230-1.","journal-title":"Eur J Cancer"},{"key":"2153_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","volume":"85","author":"E Levantini","year":"2022","unstructured":"Levantini E, Maroni G, Del Re M, et al. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol. 2022;85:253\u201375. https:\/\/doi.org\/10.1016\/j.semcancer.2022.04.002.","journal-title":"Semin Cancer Biol"},{"issue":"30","key":"2153_CR4","doi-asserted-by":"publisher","first-page":"50209","DOI":"10.18632\/oncotarget.16854","volume":"8","author":"X Liu","year":"2017","unstructured":"Liu X, Wang P, Zhang C, et al. Epidermal growth factor receptor (EGFR): a rising star in the era of precision medicine of lung cancer. Oncotarget. 2017;8(30):50209\u201320. https:\/\/doi.org\/10.18632\/oncotarget.16854.","journal-title":"Oncotarget"},{"issue":"7","key":"2153_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/s2468-1253(23)00479-x","volume":"9","author":"S Napolitano","year":"2024","unstructured":"Napolitano S, Martini G, Ciardiello D, et al. Targeting the EGFR signalling pathway in metastatic colorectal cancer. Lancet Gastroenterol Hepatol. 2024;9(7):664\u201376. https:\/\/doi.org\/10.1016\/s2468-1253(23)00479-x.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"16","key":"2153_CR6","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.2174\/1381612822666160304151011","volume":"22","author":"LS Steelman","year":"2016","unstructured":"Steelman LS, Fitzgerald T, Lertpiriyapong K, et al. Critical roles of EGFR family members in breast cancer and breast cancer stem cells: targets for therapy. Curr Pharm Des. 2016;22(16):2358\u201388. https:\/\/doi.org\/10.2174\/1381612822666160304151011.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"2153_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.drup.2011.02.004","volume":"14","author":"M Murphy","year":"2011","unstructured":"Murphy M, Stordal B. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug Resist Updat. 2011;14(3):177\u201390. https:\/\/doi.org\/10.1016\/j.drup.2011.02.004.","journal-title":"Drug Resist Updat"},{"issue":"7","key":"2153_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.62347\/dwiw6941","volume":"18","author":"H Zan","year":"2025","unstructured":"Zan H, Xu M, Guo P. Efficacy and safety of EGFR-TKI for EGFR-mutated NSCLC: systematic review and network meta-analysis. Int J Clin Exp Pathol. 2025;18(7):386\u2013404. https:\/\/doi.org\/10.62347\/dwiw6941.","journal-title":"Int J Clin Exp Pathol"},{"issue":"4","key":"2153_CR9","first-page":"505","volume":"123","author":"GJ Yuan","year":"2010","unstructured":"Yuan GJ, Ke QH, Xu XM, et al. Gefitinib-induced disseminated intravascular coagulation in a patient with non-small cell lung cancer. Chin Med J (Engl). 2010;123(4):505\u20136.","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"2153_CR10","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1378\/chest.12-2112","volume":"143","author":"B Singh","year":"2013","unstructured":"Singh B, Hanson AC, Alhurani R, et al. Trends in the incidence and outcomes of disseminated intravascular coagulation in critically ill patients (2004\u20132010): a population-based study. Chest. 2013;143(5):1235\u201342. https:\/\/doi.org\/10.1378\/chest.12-2112.","journal-title":"Chest"},{"issue":"1","key":"2153_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/01.Ccm.0000295317.97245.2d","volume":"36","author":"S Gando","year":"2008","unstructured":"Gando S, Saitoh D, Ogura H, et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med. 2008;36(1):145\u201350. https:\/\/doi.org\/10.1097\/01.Ccm.0000295317.97245.2d.","journal-title":"Crit Care Med"},{"issue":"5","key":"2153_CR12","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s12185-024-03896-9","volume":"121","author":"K Yamakawa","year":"2025","unstructured":"Yamakawa K, Okamoto K, Seki Y, et al. Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis. Int J Hematol. 2025;121(5):592\u2013604. https:\/\/doi.org\/10.1007\/s12185-024-03896-9.","journal-title":"Int J Hematol"},{"issue":"5","key":"2153_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s12185-024-03887-w","volume":"121","author":"N Kawano","year":"2025","unstructured":"Kawano N, Ikezoe T, Seki Y, et al. Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 2: hematologic malignancy. Int J Hematol. 2025;121(5):605\u201321.","journal-title":"Int J Hematol"},{"issue":"1","key":"2153_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40560-025-00794-y","volume":"13","author":"S Gando","year":"2025","unstructured":"Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. J Intensive Care. 2025;13(1):32. https:\/\/doi.org\/10.1186\/s40560-025-00794-y.","journal-title":"J Intensive Care"},{"issue":"7","key":"2153_CR15","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/j.jtha.2025.03.038","volume":"23","author":"T Iba","year":"2025","unstructured":"Iba T, Levy JH, Maier CL, et al. Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation. J Thromb Haemost. 2025;23(7):2356\u201362. https:\/\/doi.org\/10.1016\/j.jtha.2025.03.038.","journal-title":"J Thromb Haemost"},{"issue":"13","key":"2153_CR16","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1182\/blood.2020007208","volume":"139","author":"NI Popescu","year":"2022","unstructured":"Popescu NI, Lupu C, Lupu F. Disseminated intravascular coagulation and its immune mechanisms. Blood. 2022;139(13):1973\u201386. https:\/\/doi.org\/10.1182\/blood.2020007208.","journal-title":"Blood"},{"issue":"2","key":"2153_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jtha.2023.09.028","volume":"22","author":"S Gando","year":"2024","unstructured":"Gando S, Levi M, Toh CH. Trauma-induced innate immune activation and disseminated intravascular coagulation. J Thromb Haemost. 2024;22(2):337\u201351. https:\/\/doi.org\/10.1016\/j.jtha.2023.09.028.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2153_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70058","volume":"6","author":"F Gong","year":"2025","unstructured":"Gong F, Zheng X, Zhao S, et al. Disseminated intravascular coagulation: cause, molecular mechanism, diagnosis, and therapy. MedComm. 2025;6(2):e70058. https:\/\/doi.org\/10.1002\/mco2.70058.","journal-title":"MedComm"},{"issue":"5","key":"2153_CR19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/bjh.17172","volume":"192","author":"K Adelborg","year":"2021","unstructured":"Adelborg K, Larsen JB, Hvas AM. Disseminated intravascular coagulation: epidemiology, biomarkers, and management. Br J Haematol. 2021;192(5):803\u201318. https:\/\/doi.org\/10.1111\/bjh.17172.","journal-title":"Br J Haematol"},{"issue":"7","key":"2153_CR20","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/annonc\/mdr592","volume":"23","author":"F Petrelli","year":"2012","unstructured":"Petrelli F, Cabiddu M, Borgonovo K, et al. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol. 2012;23(7):1672\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdr592.","journal-title":"Ann Oncol"},{"issue":"10","key":"2153_CR21","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1002\/ijc.30280","volume":"139","author":"M Miroddi","year":"2016","unstructured":"Miroddi M, Sterrantino C, Simmonds M, et al. Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab). Int J Cancer. 2016;139(10):2370\u201380. https:\/\/doi.org\/10.1002\/ijc.30280.","journal-title":"Int J Cancer"},{"issue":"4","key":"2153_CR22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/01.cad.0000203385.45163.76","volume":"17","author":"S Kanazawa","year":"2006","unstructured":"Kanazawa S, Yamaguchi K, Kinoshita Y, et al. Aspirin reduces adverse effects of gefitinib. Anticancer Drugs. 2006;17(4):423\u20137. https:\/\/doi.org\/10.1097\/01.cad.0000203385.45163.76.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"2153_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/09537100802592692","volume":"20","author":"S Kanazawa","year":"2009","unstructured":"Kanazawa S, Yamaguchi K, Kinoshita Y, et al. Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer. Platelets. 2009;20(1):70\u20131. https:\/\/doi.org\/10.1080\/09537100802592692.","journal-title":"Platelets"},{"key":"2153_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071752","volume":"379","author":"MM Dhodapkar","year":"2022","unstructured":"Dhodapkar MM, Shi X, Ramachandran R, et al. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008\u201319: cross sectional study. BMJ. 2022;379:e071752. https:\/\/doi.org\/10.1136\/bmj-2022-071752.","journal-title":"BMJ"},{"issue":"1","key":"2153_CR25","doi-asserted-by":"publisher","first-page":"2481392","DOI":"10.1080\/14756366.2025.2481392","volume":"40","author":"D Zhang","year":"2025","unstructured":"Zhang D, Zhao J, Yang Y, et al. Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future. J Enzyme Inhib Med Chem. 2025;40(1):2481392. https:\/\/doi.org\/10.1080\/14756366.2025.2481392.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"5","key":"2153_CR26","doi-asserted-by":"publisher","first-page":"100076","DOI":"10.1016\/j.pharmr.2025.100076","volume":"77","author":"Y Du","year":"2025","unstructured":"Du Y, Karatekin F, Wang WK, et al. Cracking the EGFR code: cancer biology, resistance mechanisms, and future therapeutic frontiers. Pharmacol Rev. 2025;77(5):100076. https:\/\/doi.org\/10.1016\/j.pharmr.2025.100076.","journal-title":"Pharmacol Rev"},{"key":"2153_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103811","volume":"99","author":"A Ayati","year":"2020","unstructured":"Ayati A, Moghimi S, Salarinejad S, et al. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem. 2020;99:103811. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103811.","journal-title":"Bioorg Chem"},{"issue":"2","key":"2153_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5482\/ha-1170","volume":"32","author":"A Falanga","year":"2012","unstructured":"Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie. 2012;32(2):115\u201325. https:\/\/doi.org\/10.5482\/ha-1170.","journal-title":"Hamostaseologie"},{"key":"2153_CR29","first-page":"11","volume-title":"Cancer treatment research","author":"A Falanga","year":"2019","unstructured":"Falanga A, Schieppati F, Russo L. Pathophysiology 1. Mechanisms of thrombosis in cancer patients. In: Soff G, editor. Cancer treatment research. Cham: Springer; 2019. p. 11\u201336."},{"issue":"19","key":"2153_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e38831","volume":"10","author":"Q Peng","year":"2024","unstructured":"Peng Q, Zhu J, Zhang Y, et al. Blood hypercoagulability and thrombosis mechanisms in cancer patients -a brief review. Heliyon. 2024;10(19):e38831. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38831.","journal-title":"Heliyon"},{"issue":"3","key":"2153_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0049-3848(95)00170-v","volume":"80","author":"H Asakura","year":"1995","unstructured":"Asakura H, Kamikubo Y, Goto A, et al. Role of tissue factor in disseminated intravascular coagulation. Thromb Res. 1995;80(3):217\u201324. https:\/\/doi.org\/10.1016\/0049-3848(95)00170-v.","journal-title":"Thromb Res"},{"issue":"5","key":"2153_CR32","doi-asserted-by":"publisher","first-page":"300060521101409","DOI":"10.1177\/03000605211014094","volume":"49","author":"S Meng","year":"2021","unstructured":"Meng S, Kang K, Fei D, et al. Preliminary study of microparticle coagulation properties in septic patients with disseminated intravascular coagulation. J Int Med Res. 2021;49(5):3000605211014094. https:\/\/doi.org\/10.1177\/03000605211014094.","journal-title":"J Int Med Res"},{"key":"2153_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/jir.S337559","volume":"15","author":"S Jiang","year":"2022","unstructured":"Jiang S, Ma J, Ye S, et al. Associations among disseminated intravascular coagulation, thrombocytopenia cytokines\/chemokines and genetic polymorphisms of toll-like receptor 2\/4 in Chinese patients with sepsis. J Inflamm Res. 2022;15:1\u201315. https:\/\/doi.org\/10.2147\/jir.S337559.","journal-title":"J Inflamm Res"},{"issue":"1","key":"2153_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12959-022-00390-2","volume":"20","author":"H Mori","year":"2022","unstructured":"Mori H, Kataoka Y, Harada-Shirado K, et al. Prognostic value of serum high mobility group box 1 protein and histone H3 levels in patients with disseminated intravascular coagulation: a multicenter prospective cohort study. Thromb J. 2022;20(1):33. https:\/\/doi.org\/10.1186\/s12959-022-00390-2.","journal-title":"Thromb J"},{"issue":"3","key":"2153_CR35","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/aln.0000000000005023","volume":"141","author":"E Scarlatescu","year":"2024","unstructured":"Scarlatescu E, Iba T, Maier CL, et al. Deranged balance of hemostasis and fibrinolysis in disseminated intravascular coagulation: assessment and relevance in different clinical settings. Anesthesiology. 2024;141(3):570\u201383. https:\/\/doi.org\/10.1097\/aln.0000000000005023.","journal-title":"Anesthesiology"},{"issue":"2","key":"2153_CR36","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/shk.0000000000001504","volume":"54","author":"T Abe","year":"2020","unstructured":"Abe T, Kubo K, Izumoto S, et al. Complement activation in human sepsis is related to sepsis-induced disseminated intravascular coagulation. Shock. 2020;54(2):198\u2013204. https:\/\/doi.org\/10.1097\/shk.0000000000001504.","journal-title":"Shock"},{"key":"2153_CR37","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.16527","volume":"11","author":"L Chen","year":"2023","unstructured":"Chen L, Lin J, Chen Y, et al. Clinicopathologic features and prognosis of 71 patients with gastric cancer and disseminated intravascular coagulation. PeerJ. 2023;11:e16527. https:\/\/doi.org\/10.7717\/peerj.16527.","journal-title":"PeerJ"},{"key":"2153_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.thromres.2023.10.005","volume":"231","author":"HY Yhim","year":"2023","unstructured":"Yhim HY, Lee J, Kim KH, et al. Increased risk of venous and arterial thromboembolism in patients with colorectal cancer receiving cetuximab-based combination chemotherapy: a population-based study in Korea. Thromb Res. 2023;231:50\u20137. https:\/\/doi.org\/10.1016\/j.thromres.2023.10.005.","journal-title":"Thromb Res"},{"key":"2153_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.thromres.2021.12.019","volume":"210","author":"F Petrelli","year":"2022","unstructured":"Petrelli F, Cabiddu M, Borgonovo K, et al. Osimertinib-related venous thromboembolism in non small lung cancer. Thromb Res. 2022;210:63\u20136. https:\/\/doi.org\/10.1016\/j.thromres.2021.12.019.","journal-title":"Thromb Res"},{"key":"2153_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.thromres.2018.05.004","volume":"167","author":"K Young","year":"2018","unstructured":"Young K, Paz-Ares L, Thatcher N, et al. Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: a retrospective cohort analysis. Thromb Res. 2018;167:50\u20136. https:\/\/doi.org\/10.1016\/j.thromres.2018.05.004.","journal-title":"Thromb Res"},{"issue":"22","key":"2153_CR41","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus chemotherapy in NSCLC with EGFR Exon 20 insertions. N Engl J Med. 2023;389(22):2039\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2306441.","journal-title":"N Engl J Med"},{"issue":"6","key":"2153_CR42","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1056\/NEJMc2314937","volume":"390","author":"F Moik","year":"2024","unstructured":"Moik F, Riedl JM, Ay C. VTE with Amivantamab plus chemotherapy in NSCLC. N Engl J Med. 2024;390(6):578\u20139. https:\/\/doi.org\/10.1056\/NEJMc2314937.","journal-title":"N Engl J Med"},{"key":"2153_CR43","doi-asserted-by":"publisher","first-page":"1573353","DOI":"10.3389\/fphar.2025.1573353","volume":"16","author":"TA Hammad","year":"2025","unstructured":"Hammad TA, Naylor M, Ely DM, et al. Exploring the complexities of disproportionality analysis in pharmacovigilance: reflections on the READUS-PV guideline and a call to action. Front Pharmacol. 2025;16:1573353. https:\/\/doi.org\/10.3389\/fphar.2025.1573353.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2153_CR44","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/0300060517720099","volume":"46","author":"JS Kim","year":"2018","unstructured":"Kim JS, Ryu JS, Jeon SH, et al. Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation. J Int Med Res. 2018;46(1):533\u20137. https:\/\/doi.org\/10.1177\/0300060517720099.","journal-title":"J Int Med Res"},{"issue":"8","key":"2153_CR45","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1016\/j.cllc.2022.09.004","volume":"23","author":"JL Pevner","year":"2022","unstructured":"Pevner JL, Tanvetyanon T. Targeted therapy for lung cancer with paraneoplastic disseminated intravascular coagulation: a case report and pooled analysis. Clin Lung Cancer. 2022;23(8):e540\u20134. https:\/\/doi.org\/10.1016\/j.cllc.2022.09.004.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"2153_CR46","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34033","volume":"15","author":"Y Ahmad","year":"2023","unstructured":"Ahmad Y, Tanvetyanon T. Amivantamab for metastatic lung cancer with paraneoplastic disseminated intravascular coagulation: a case report. Cureus. 2023;15(1):e34033. https:\/\/doi.org\/10.7759\/cureus.34033.","journal-title":"Cureus"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02153-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02153-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02153-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:31:03Z","timestamp":1784035863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02153-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["2153"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02153-9","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Since the FAERS database is an open-access resource with anonymized patient data, this study was exempt from ethical review and informed consent requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}